Literature DB >> 22568401

Frequent BRAF gain in low-grade diffuse gliomas with 1p/19q loss.

Young-Ho Kim1, Naosuke Nonoguchi, Werner Paulus, Benjamin Brokinkel, Kathy Keyvani, Ulrich Sure, Karsten Wrede, Luigi Mariani, Felice Giangaspero, Yuko Tanaka, Yoichi Nakazato, Anne Vital, Michel Mittelbronn, Arie Perry, Hiroko Ohgaki.   

Abstract

Chromosomal 7q34 duplication and BRAF-KIAA1549 fusion is a characteristic genetic alteration in pilocytic astrocytomas. 7q34 gain appears to be common in diffuse astrocytomas, but its significance is unclear. We assessed BRAF gain and BRAF mutations in 123 low-grade diffuse gliomas, including 55 diffuse astrocytomas, 18 oligoastrocytomas and 50 oligodendrogliomas. Quantitative polymerase chain reaction (PCR) revealed BRAF gain in 17/50 (34%) oligodendrogliomas, a significantly higher frequency than in diffuse astrocytomas (7/55; 13%; P = 0.0112). BRAF gain was common in low-grade diffuse gliomas with 1p/19q loss (39%) and those lacking any of the genetic alterations analyzed (31%), but was rare in those with TP53 mutations (2%). Logistic regression analysis showed a significant positive association between 1p/19q loss and BRAF gain (P = 0.0032) and a significant negative association between TP53 mutations and BRAF gain (P = 0.0042). Fluorescence in situ hybridization (FISH) analysis of 26 low-grade diffuse gliomas with BRAF gain additionally revealed BRAF-KIAA1549 fusion in one oligodendroglioma. Sequencing of cDNA in 17 low-grade diffuse gliomas showed BRAF-KIAA1549 fusion in another oligodendroglioma. A BRAF(V600E) mutation was also detected in one oligodendroglioma, and a BRAF(A598V) in one diffuse astrocytoma. These results suggest that low-grade diffuse gliomas with 1p/19q loss have frequent BRAF gains, and a small fraction of oligodendrogliomas may show BRAF-KIAA1549 fusion.
© 2012 The Authors; Brain Pathology © 2012 International Society of Neuropathology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22568401     DOI: 10.1111/j.1750-3639.2012.00601.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  12 in total

1.  High rate of concurrent BRAF-KIAA1549 gene fusion and 1p deletion in disseminated oligodendroglioma-like leptomeningeal neoplasms (DOLN).

Authors:  Fausto J Rodriguez; Matthew J Schniederjan; Theo Nicolaides; Tarik Tihan; Peter C Burger; Arie Perry
Journal:  Acta Neuropathol       Date:  2015-02-27       Impact factor: 17.088

2.  PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma.

Authors:  Joanna J Phillips; Derick Aranda; David W Ellison; Alexander R Judkins; Sidney E Croul; Daniel J Brat; Keith L Ligon; Craig Horbinski; Sriram Venneti; Gelareh Zadeh; Mariarita Santi; Shengmei Zhou; Christina L Appin; Stefano Sioletic; Lisa M Sullivan; Maria Martinez-Lage; Aaron E Robinson; William H Yong; Timothy Cloughesy; Albert Lai; Heidi S Phillips; Roxanne Marshall; Sabine Mueller; Daphne A Haas-Kogan; Annette M Molinaro; Arie Perry
Journal:  Brain Pathol       Date:  2013-03-18       Impact factor: 6.508

3.  Reactive retinal astrocytic tumors (so-called vasoproliferative tumors): histopathologic, immunohistochemical, and genetic studies of four cases.

Authors:  Lynn J Poole Perry; Frederick A Jakobiec; Fouad R Zakka; Elias Reichel; Martina C Herwig; Arie Perry; Daniel J Brat; Hans E Grossniklaus
Journal:  Am J Ophthalmol       Date:  2012-12-06       Impact factor: 5.258

4.  Adult pilocytic astrocytomas: clinical features and molecular analysis.

Authors:  Brett J Theeler; Benjamin Ellezam; Zsila S Sadighi; Vidya Mehta; M Diep Tran; Adekunle M Adesina; Janet M Bruner; Vinay K Puduvalli
Journal:  Neuro Oncol       Date:  2014-01-26       Impact factor: 12.300

5.  Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification.

Authors:  Midea Gierke; Jan Sperveslage; David Schwab; Rudi Beschorner; Martin Ebinger; Martin U Schuhmann; Jens Schittenhelm
Journal:  J Cancer Res Clin Oncol       Date:  2015-06-27       Impact factor: 4.553

Review 6.  Spinal cord tumours: advances in genetics and their implications for treatment.

Authors:  Patricia L Zadnik; Ziya L Gokaslan; Peter C Burger; Chetan Bettegowda
Journal:  Nat Rev Neurol       Date:  2013-03-26       Impact factor: 42.937

7.  Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation.

Authors:  Andrew J Dodgshun; Nadine SantaCruz; Jaeho Hwang; Shakti H Ramkissoon; Hayley Malkin; Guillaume Bergthold; Peter Manley; Susan Chi; Duncan MacGregor; Liliana Goumnerova; Michael Sullivan; Keith Ligon; Rameen Beroukhim; Betty Herrington; Mark W Kieran; Jordan R Hansford; Pratiti Bandopadhayay
Journal:  J Neurooncol       Date:  2016-03-19       Impact factor: 4.130

8.  The differential diagnosis of pilocytic astrocytoma with atypical features and malignant glioma: an analysis of 16 cases with emphasis on distinguishing molecular features.

Authors:  Matthew D Cykowski; Richard A Allen; Angela C Kanaly; Kar-Ming Fung; Roxanne Marshall; Arie Perry; Ethan D Stolzenberg; S Terence Dunn
Journal:  J Neurooncol       Date:  2013-09-21       Impact factor: 4.506

Review 9.  Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods.

Authors:  Rafay Ahmed; Matthew J Oborski; Misun Hwang; Frank S Lieberman; James M Mountz
Journal:  Cancer Manag Res       Date:  2014-03-24       Impact factor: 3.989

10.  Biomarkers classification and therapeutic decision-making for malignant gliomas.

Authors:  Adriana Olar; Kenneth D Aldape
Journal:  Curr Treat Options Oncol       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.